Milestone Scientific Launches CompuFlo Advisor Program to Accelerate Commercial Adoption and Drive Utilization Growth in Select MAC Jurisdictions; Plans National Expansion

ROSELAND, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced the launch of the CompuFlo® Advisor Program. This strategic initiative is designed to drive mainstream commercial adoption, increase recurring disposable revenue, and generate the clinical data necessary to optimize long-term Medicare reimbursement rates.

The program, which commenced on February 1, 2026, targets high-volume interventional pain and anesthesia practices within key Medicare Administrative Contractor (MAC) jurisdictions, including Novitas, First Coast, Noridian, and Palmetto. These jurisdictions represent a strategic first phase of execution, with infrastructure designed to support phased expansion across additional MAC regions throughout the United States. By engaging Key Opinion Leaders (KOLs) to generate a targeted 1,000–2,000 case submissions in the initial six-month phase, Milestone is executing a structured clinical and reimbursement roadmap to transition CPT® code 0777T from Category III to Category I status, that could enhance commercial adoption and long-term revenue visibility.

To ensure the program delivers a scalable recurring revenue model, Milestone has deployed a robust commercial infrastructure designed to support national expansion. The Company has also engaged industry veterans, including Evelyn Gittinger, CPC, and Neuro Management Solutions (NMS), to provide real-time claims support, documentation guidance, and payer advocacy.

"The Advisor Program is a key strategic initiative for Milestone Scientific this year," stated Eric Hines, CEO of Milestone Scientific. "We have moved beyond simply placing devices to building a comprehensive commercial ecosystem. We are deploying a 'white glove' support infrastructure, including veteran consultants and a dedicated provider hotline, to support our physicians through every step of the reimbursement process. With favorable unit economics and a scalable model, we believe establishing reimbursement with this initial cohort will unlock a recurring revenue flywheel that can be rapidly expanded to hundreds of physicians nationwide."

About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology

instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the